Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007721 | 0.89 | MAPK14 (0.55) | GFERMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4251779 | 0.86 | LMNA (0.45) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL5007746 | 0.84 | GFER (0.51) | GFERMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5010659 | 0.84 | MAPK14 (0.64) | GFERMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3973341 | 0.83 | MAPK14 (0.40) | GFERMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5012181 | 0.82 | ADORA1 (0.51) | GFERMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5007743 | 0.82 | CLCN2 (0.51) | GFERMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5010672 | 0.81 | MAPK14 (0.59) | GFERMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3983567 | 0.81 | DHODH (0.41) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL5008499 | 0.81 | NTRK1 (0.52) | GFERMAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | claimed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | claimed |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | claimed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | GFER 1604/4885MAPK14 1938/4885MAPK13 885/4885 |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | GFER 1604/4885MAPK14 1938/4885MAPK13 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.